Inventor · disambiguated record
Dedong Wu
Also filed as: WU DEDONG
13 granted patents·4 pending applications·34 citations·filing 2010–2024
89Inventor score
Files withASTRAZENECA AB12Beiture LLP1DIZAL JIANGSU PHARMACEUTICAL CO LTD1JIANGXI FUSHINE PHARMACEUTICAL CO LTD1LONGEVITAN BIOSCIENCES LLC1
Top patents by PatentIndex Score
17 records- 0195US11912727B2Arginase inhibitors and methods of use thereofASTRAZENECA AB·Filed 2023·Granted Feb 27, 2024·4 cites·13 claims
- 0294US12195485B2Arginase inhibitors and methods of use thereofASTRAZENECA AB·Filed 2022·Granted Jan 14, 2025·4 cites·23 claims
- 0390US11345697B1Crystalline berberine ascorbate salt, methods of preparation and applications thereofWU DEDONG·Filed 2020·Granted May 31, 2022·5 cites·11 claims
- 0489US11420984B2Arginase inhibitors and methods of use thereofASTRAZENECA AB·Filed 2019·Granted Aug 23, 2022·7 cites·19 claims
- 0589US9840518B2MCL-1 inhibitors and methods of use thereofASTRAZENECA AB·Filed 2017·Granted Dec 12, 2017·9 cites·4 claims
- 0685US11952392B2Arginase inhibitors and methods of use thereofASTRAZENECA AB·Filed 2019·Granted Apr 9, 2024·2 cites·27 claims
- 0782US2025313578A1Arginase Inhibitors and Methods of Use ThereofASTRAZENECA AB·Filed 2024·Application pending·0 cites
- 0875US12319670B2Compounds and methods for inhibiting JAKDIZAL JIANGSU PHARMACEUTICAL CO LTD·Filed 2021·Granted Jun 3, 2025·0 cites·24 claims
- 0970US10577379B1Fenofibric acid salt with berberine or its analogues, crystalline forms, methods of preparation, and applications thereofJIANGXI FUSHINE PHARMACEUTICAL CO LTD·Filed 2019·Granted Mar 3, 2020·3 cites·20 claims
- 1069US11472816B2Mcl-1 inhibitors and methods of use thereofASTRAZENECA AB·Filed 2020·Granted Oct 18, 2022·0 cites·9 claims
- 1167US10889594B2MCL-1 inhibitors and methods of use thereofASTRAZENECA AB·Filed 2018·Granted Jan 12, 2021·0 cites·10 claims
- 1264US12358922B1Berberine alpha-ketoglutarate salt, crystalline form, methods of preparation and applications thereofLONGEVITAN BIOSCIENCES LLC·Filed 2024·Granted Jul 15, 2025·0 cites·15 claims
- 1359US10196404B2MCL-1 inhibitors and methods of use thereofASTRAZENECA AB·Filed 2017·Granted Feb 5, 2019·0 cites·4 claims
- 1457US2024374606A1Substituted pyrazine-2-carboxamides as hpk1 inhibitors for the treatment of cancerASTRAZENECA AB·Filed 2022·Application pending·0 cites
- 1555US10149839B2Chemical compoundsASTRAZENECA AB·Filed 2017·Granted Dec 11, 2018·0 cites·8 claims
- 1654US2025026777A1Cocrystals of nicotinamide riboside salts, crystalline forms, methods of preparation, and applications thereofBeiture LLP·Filed 2023·Application pending·0 cites
- 1729US2011207745A1Solid forms of 4--n,n-diethylbenzamide, compositions thereof, and uses therewithASTRAZENECA AB·Filed 2010·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →